Drugmaker Pfizer Inc., which acquired pharmaceutical rival, Wyeth in October, announced they would begin streamlining on Wednesday. The company plans to begin by discontinuing research on over 100 of their combined experimental drugs in order to concentrate their resources on more vital areas.
Even after abandoning over 100 undertakings Pfizer remains committed to roughly 500 research projects with 75 percent of them in the final stages of completion within six fundamental focus areas.
Cancer, pain, Alzheimer's disease, diabetes, inflammation and mental illnesses are the focus for Pfizer, who at present, believe these categories need improvements in treatment. The company is also working on vaccines and biologic drugs since their $68 billion acquisition of Wyeth gave them access to the company’s vaccines and biotech drugs.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription
